Total medical devices industry cross border M&A deals worth $4.64bn were announced globally in Q1 2021, led by Boston Scientific’s $1.07bn asset transaction with Lumenis, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 2.4% over the previous quarter of $4.53bn and a drop of 23.2% when compared with the last four-quarter average, which stood at $6.04bn.
Comparing cross border M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $2.37bn. At the country level, the Belgium topped the list in terms of deal value at $1.15bn.
In terms of volumes, Europe emerged as the top region for medical devices industry cross border M&A deals globally, followed by North America and then Asia-Pacific.
The top country in terms of cross border M&A deals activity in Q1 2021 was the US with 17 deals, followed by Canada with seven and Germany with seven.
In 2021, at the end of , cross border M&A deals worth $4.64bn were announced globally in medical devices industry, marking a decrease of 720.3% year on year.
Cross Border M&A deals in medical devices industry in Q1 2021: Top deals
The top five cross border M&A deals in medical devices industry accounted for 77.3% of the overall value during Q1 2021.
The combined value of the top deals stood at $3.59bn, against the overall value of $4.64bn recorded for the quarter.
The top five medical devices industry cross border medical devices deals of Q1 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific
3) Koninklijke Philips’ $635m acquisition of Capsule Technologies
4) The $591m acquisition of Oxford Immunotec by PerkinElmer
5) Savaria’s acquisition of Handicare Group for $409.7m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.